Canaccord Genuity Believes Heska Corp (HSKA) Still Has Room to Grow


Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Heska Corp (NASDAQ: HSKA) today and set a price target of $123. The company’s shares closed yesterday at $106.75, close to its 52-week high of $115.

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.7% and a 64.2% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Orasure Technologies, and Idexx Laboratories.

Heska Corp has an analyst consensus of Moderate Buy, with a price target consensus of $112.

See today’s analyst top recommended stocks >>

Based on Heska Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $2.16 million. In comparison, last year the company had a net profit of $4.61 million.

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. Last month, Bonnie Trowbridge, a Director at HSKA sold 5,000 shares for a total of $505,029.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the Core Companion Animal Health; and Other Vaccines, and Pharmaceuticals and Products segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts